Endothelial hyperpermeability in severe pulmonary arterial hypertension: Role of store-operated calcium entry

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 311, Issue 3, 2016, Pages L560-L569

  Zhou, Chun ^a,b   Townsley, Mary I ^a,b   Alexeyev, Mikhail ^a,b   Voelkel, Norbert F ^c   Stevens, Troy ^a,b  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium channels; Canonical transient receptor potential 4; Edema; Filtration coefficient; Semaxanib; Sugen 5416; TRPC4

Indexed keywords

DNA; SEMAXANIB; THAPSIGARGIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL 4; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRPC4 ION CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; BRONCHOALVEOLAR LAVAGE FLUID; CELL MEMBRANE PERMEABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DNA EXTRACTION; DOSE RESPONSE; GENOTYPE; HEART RIGHT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HYPOXIA; LUNG ARTERY PRESSURE; LUNG ENDOTHELIUM; LUNG PERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; ANIMAL; ARTERIAL PRESSURE; CALCIUM SIGNALING; CELL HYPOXIA; DRUG EFFECTS; FISCHER 344 RAT; GENETICS; METABOLISM; PATHOLOGY; PERMEABILITY; VASCULAR ENDOTHELIUM;

ANIMALS; ARTERIAL PRESSURE; CALCIUM SIGNALING; CELL HYPOXIA; ENDOTHELIUM, VASCULAR; HYPERTENSION, PULMONARY; INDOLES; MALE; PERMEABILITY; PYRROLES; RATS, INBRED F344; THAPSIGARGIN; TRPC CATION CHANNELS;

EID: 84986551458     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00057.2016     Document Type: Article

References (71)

1. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121: 2747–2754, 2010.
2. Alvarez DF, Gjerde EA, Townsley MI. Role of EETs in regulation of endothelial permeability in rat lung. Am J Physiol Lung Cell Mol Physiol 286: L445–L451, 2004.
3. Alvarez DF, King JA, Townsley MI. Resistance to store depletioninduced endothelial injury in rat lung after chronic heart failure. Am J Respir Crit Care Med 172: 1153–1160, 2005.
4. Alvarez DF, King JA, Weber D, Addison E, Liedtke W, Townsley MI. Transient receptor potential vanilloid 4-mediated disruption of the alveolar septal barrier: a novel mechanism of acute lung injury. Circ Res 99: 988–995, 2006.
5. Alzoubi A, Almalouf P, Toba M, O’Neill K, Qian X, Francis M, Taylor MS, Alexeyev M, McMurtry IF, Oka M, Stevens T. TRPC4 inactivation confers a survival benefit in severe pulmonary arterial hypertension. Am J Pathol 183: 1779–1788, 2013.
6. 2+ entry pathway. FASEB J 15: 1727–1738, 2001.
7. Burton VJ, Ciuclan LI, Holmes AM, Rodman DM, Walker C, Budd DC. Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function. Blood 117: 333–341, 2011.
8. Burton VJ, Holmes AM, Ciuclan LI, Robinson A, Roger JS, Jarai G, Pearce AC, Budd DC. Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II. Blood 118: 4750–4758, 2011.
9. Butler WH. An ultrastructural study of the pulmonary lesion induced by pyrrole derivatives of the pyrrolizidine alkaloids. J Pathol 102: 15–19, 1970.
10. Cassee FR, Boere AJ, Bos J, Fokkens PH, Dormans JA, van Loveren H. Effects of diesel exhaust enriched concentrated PM2.5 in ozone preexposed or monocrotaline-treated rats. Inhal Toxicol 14: 721–743, 2002.
11. 2+ entry. Am J Physiol Lung Cell Mol Physiol 276: L41–L50, 1999.
12. Cinelli P, Rettich A, Seifert B, Burki K, Arras M. Comparative analysis and physiological impact of different tissue biopsy methodologies used for the genotyping of laboratory mice. Lab Anim 41: 174–184, 2007.
13. Cioffi DL, Barry C, Stevens T. Store-operated calcium entry channels in pulmonary endothelium: the emerging story of TRPCS and Orai1. Adv Exp Med Biol 661: 137–154, 2010.
14. Cioffi DL, Lowe K, Alvarez DF, Barry C, Stevens T. TRPing on the lung endothelium: calcium channels that regulate barrier function. Antioxid Redox Signal 11: 765–776, 2009.
15. Cioffi DL, Stevens T. Regulation of endothelial cell barrier function by store-operated calcium entry. Microcirculation 13: 709–723, 2006.
16. 2+ channel requires interaction of protein 4.1 with TRPC4. Circ Res 97: 1164–1172, 2005.
17. Cioffi DL, Wu S, Chen H, Alexeyev M, St Croix CM, Pitt BR, Uhlig S, Stevens T. Orai1 determines calcium selectivity of an endogenous TRPC heterotetramer channel. Circ Res 110: 1435–1444, 2012.
18. Cioffi DL, Wu S, Stevens T. On the endothelial cell ISOC. Cell Calcium 33: 323–336, 2003.
19. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 28: 434–442, 1997.
20. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, Tuder RM. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 155: 411–419, 1999.
21. Farhat MY, Chen MF, Bhatti T, Iqbal A, Cathapermal S, Ramwell PW. Protection by oestradiol against the development of cardiovascular changes associated with monocrotaline pulmonary hypertension in rats. Br J Pharmacol 110: 719–723, 1993.
22. Fishman AP. Changing concepts of the pulmonary plexiform lesion. Physiol Res 49: 485–492, 2000.
23. Francis M, Xu N, Zhou C, Stevens T. TRPC4 encodes high frequency calcium transients in severe pulmonary arterial hypertension. Am J Pathol 186: 1701–1709, 2016.
24. Ganey PE, Sprugel KH, Hadley KB, Roth RA. Monocrotaline pyrroleinduced cardiopulmonary toxicity is not altered by metergoline or ketanserin. J Pharmacol Exp Ther 237: 226–231, 1986.
25. Ganey PE, Sprugel KH, White SM, Wagner JG, Roth RA. Pulmonary hypertension due to monocrotaline pyrrole is reduced by moderate thrombocytopenia. Am J Physiol Heart Circ Physiol 255: H1165–H1172, 1988.
26. He LS, Chang SW, Voelkel NF. Pulmonary vascular reactivity in Fischer rats. J Appl Physiol (1985) 70: 1861–1866, 1991.
27. Hilliker KS, Bell TG, Lorimer D, Roth RA. Effects of thrombocytopenia on monocrotaline pyrrole-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 246: H747–H753, 1984.
28. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43: 13S–24S, 2004.
29. Ilkiw R, Todorovich-Hunter L, Maruyama K, Shin J, Rabinovitch M. SC-39026, a serine elastase inhibitor, prevents muscularization of peripheral arteries, suggesting a mechanism of monocrotaline-induced pulmonary hypertension in rats. Circ Res 64: 814–825, 1989.
30. 2+ signaling. Am J Physiol Heart Circ Physiol 275: H844–H851, 1998.
31. Jiang B, Deng Y, Suen C, Taha M, Chaudhary KR, Courtman DW, Stewart DJ. Marked strain-specific differences in the SU5416 rat model of severe pulmonary arterial hypertension. Am Rev Respir Crit Care Med 54: 461–468, 2015.
32. Johnson JA, Hemnes AR, Perrien DS, Schuster M, Robinson LJ, Gladson S, Loibner H, Bai S, Blackwell TR, Tada Y, Harral JW, Talati M, Lane KB, Fagan KA, West J. Cytoskeletal defects in Bmpr2- associated pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 302: L474–L484, 2012.
33. Long L, Crosby A, Yang X, Southwood M, Upton PD, Kim DK, Morrell NW. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 119: 566–576, 2009.
34. Long L, Ormiston ML, Yang X, Southwood M, Graf S, Machado RD, Mueller M, Kinzel B, Yung LM, Wilkinson JM, Moore SD, Drake KM, Aldred MA, Yu PB, Upton PD, Morrell NW. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med 21: 777–785, 2015.
35. Lowe K, Alvarez D, King J, Stevens T. Phenotypic heterogeneity in lung capillary and extra-alveolar endothelial cells. Increased extra-alveolar endothelial permeability is sufficient to decrease compliance. J Surg Res 143: 70–77, 2007.
36. Lowe K, Alvarez DF, King JA, Stevens T. Perivascular fluid cuffs decrease lung compliance by increasing tissue resistance. Crit Care Med 38: 1458–1466, 2010.
37. McMurtry IF, Abe K, Ota H, Fagan KA, Oka M. Rho kinase-mediated vasoconstriction in pulmonary hypertension. Adv Exp Med Biol 661: 299–308, 2010.
38. Murugesan P, Hildebrandt T, Bernlohr C, Lee D, Khang G, Doods H, Wu D. Inhibition of kinin B1 receptors attenuates pulmonary hypertension and vascular remodeling. Hypertension 66: 906–912, 2015.
39. Nagaoka T, Morio Y, Casanova N, Bauer N, Gebb S, McMurtry I, Oka M. Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 287: L665–L672, 2004.
40. Newman JH, Fanburg BL, Archer SL, Badesch DB, Barst RJ, Garcia JG, Kao PN, Knowles JA, Loyd JE, McGoon MD, Morse JH, Nichols WC, Rabinovitch M, Rodman DM, Stevens T, Tuder RM, Voelkel NF, Gail DB. Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation 109: 2947–2952, 2004.
41. Oka M, Hasunuma K, Webb SA, Stelzner TJ, Rodman DM, Mc- Murtry IF. EDRF suppresses an unidentified vasoconstrictor mechanism in hypertensive rat lungs. Am J Physiol Lung Cell Mol Physiol 264: L587–L597, 1993.
42. Palevsky HI, Schloo BL, Pietra GG, Weber KT, Janicki JS, Rubin E, Fishman AP. Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation 80: 1207–1221, 1989.
43. Pan LC, Wilson DW, Segall HJ. Strain differences in the response of Fischer 344 and Sprague-Dawley rats to monocrotaline induced pulmonary vascular disease. Toxicology 79: 21–35, 1993.
44. Parker JC, Townsley MI. Evaluation of lung injury in rats and mice. Am J Physiol Lung Cell Mol Physiol 286: L231–L246, 2004.
45. Parker JC, Townsley MI. Physiological determinants of the pulmonary filtration coefficient. Am J Physiol Lung Cell Mol Physiol 295: L235–L237, 2008.
46. Plestina R, Stoner HB. Pulmonary oedema in rats given monocrotaline pyrrole. J Pathol 106: 235–249, 1972.
47. Prewitt AR, Ghose S, Frump AL, Datta A, Austin ED, Kenworthy AK, de Caestecker MP. Heterozygous null bone morphogenetic protein receptor type 2 mutations promote SRC kinase-dependent caveolar trafficking defects and endothelial dysfunction in pulmonary arterial hypertension. J Biol Chem 290: 960–971, 2015.
48. Qin L, D’Alessandro-Gabazza CN, Aoki S, Gil-Bernabe P, Yano Y, Takagi T, Boveda-Ruiz D, Ramirez Marmol AY, San Martin Montenegro VT, Toda M, Miyake Y, Taguchi O, Takei Y, Morser J, Gabazza EC. Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 8: 808–816, 2010.
49. Rai PR, Cool CD, King JA, Stevens T, Burns N, Winn RA, Kasper M, Voelkel NF. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 178: 558–564, 2008.
50. Reindel JF, Ganey PE, Wagner JG, Slocombe RF, Roth RA. Development of morphologic, hemodynamic, and biochemical changes in lungs of rats given monocrotaline pyrrole. Toxicol Appl Pharmacol 106: 179–200, 1990.
51. Reynolds AM, Holmes MD, Danilov SM, Reynolds PN. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. Eur Respir J 39: 329–343, 2012.
52. Rosenberg HC, Rabinovitch M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol Heart Circ Physiol 255: H1484–H1491, 1988.
53. Schnader J, Schloo BL, Anderson W, Stephenson LW, Fishman AP. Chronic pulmonary hypertension in sheep: temporal progression of lesions. J Surg Res 62: 243–250, 1996.
54. Schultze AE, Wagner JG, White SM, Roth RA. Early indications of monocrotaline pyrrole-induced lung injury in rats. Toxicol Appl Pharmacol 109: 41–50, 1991.
55. Shimoda LA, Sham JS, Sylvester JT. Altered pulmonary vasoreactivity in the chronically hypoxic lung. Physiol Res 49: 549–560, 2000.
56. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54: S43–54, 2009.
57. Smith P, Heath D. Electron microscopy of the plexiform lesion. Thorax 34: 177–186, 1979.
58. Smith P, Heath D, Yacoub M, Madden B, Caslin A, Gosney J. The ultrastructure of plexogenic pulmonary arteriopathy. J Pathol 160: 111–121, 1990.
59. Sugita T, Hyers TM, Dauber IM, Wagner WW, McMurtry IF, Reeves JT. Lung vessel leak precedes right ventricular hypertrophy in monocrotaline- treated rats. J Appl Physiol Respir Environ Exercise Physiol 54: 371–374, 1983.
60. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15: 427–438, 2001.
61. 2+ entry in TRPC4(−/−) mice interferes with increase in lung microvascular permeability. Circ Res 91: 70–76, 2002.
62. 2+ channels and pulmonary endothelial permeability: insights from study of intact lung and chronic pulmonary hypertension. Microcirculation 13: 725–739, 2006.
63. Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF. The pathobiology of pulmonary hypertension. Endothelium Clin Chest Med 22: 405–418, 2001.
64. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144: 275–285, 1994.
65. Tuder RM, Voelkel NF. Angiogenesis and pulmonary hypertension: a unique process in a unique disease. Antioxid Redox Signal 4: 833–843, 2002.
66. Tuder RM, Voelkel NF. Plexiform lesion in severe pulmonary hypertension: association with glomeruloid lesion. Am J Pathol 159: 382–383, 2001.
67. West J, Fagan K, Steudel W, Fouty B, Lane K, Harral J, Hoedt-Miller M, Tada Y, Ozimek J, Tuder R, Rodman DM. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 94: 1109–1114, 2004.
68. White SM, Roth RA. Pulmonary platelet sequestration is increased following monocrotaline pyrrole treatment of rats. Toxicol Appl Pharmacol 96: 465–475, 1988.
69. White SM, Wagner JG, Roth RA. Effects of altered platelet number on pulmonary hypertension and platelet sequestration in monocrotaline pyrrole- treated rats. Toxicol Appl Pharmacol 99: 302–313, 1989.
70. 2+-selective, store-operated current (ISOC) in endothelial cell permeability: determinants of the vascular leak site. Circ Res 96: 856–863, 2005.
71. Yamaki S, Wagenvoort CA. Plexogenic pulmonary arteriopathy: significance of medial thickness with respect to advanced pulmonary vascular lesions. Am J Pathol 105: 70–75, 1981.